FoRT 05- BEAT Phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in PD-L1 high advanced non-small-cell lung cancer patients

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517200-10-00

Enrollment

130

Registered

2024-11-26

Start date

2020-01-31

Completion date

Unknown

Last updated

2025-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced non-small-cell lung cancer

Brief summary

Overall Survival (OS) in patients treated with atezolizumab alone versus atezolizumab-bevacizumab combination

Interventions

DRUGAvastin 25 mg/ml concentrate for solution for infusion.

DRUGTecentriq 1 200 mg concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall Survival (OS) in patients treated with atezolizumab alone versus atezolizumab-bevacizumab combination	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026